Drug and treatment costs in Parkinson's disease patients in Sweden

Acta Neurologica Scandinavica

Volumn 125, Issue 2, 2012, Pages 142-147

  Lokk J ^a   Borg, S ^b   Svensson, J ^b   Persson, U ^b   Ljunggren, G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

Author keywords

Drug costs; Healthcare; Parkinson's disease; Prevalence; Treatment

Indexed keywords

ADULT; AGED; ARTICLE; CAREGIVER; DISEASE REGISTRY; DRUG COST; DRUG MARKETING; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PARKINSON DISEASE; PATIENT CARE; PREVALENCE; REIMBURSEMENT; SWEDEN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; DELIVERY OF HEALTH CARE; FEMALE; HEALTH CARE COSTS; HUMANS; INFANT; MALE; MIDDLE AGED; PARKINSON DISEASE; SWEDEN; YOUNG ADULT;

EID: 84855965901     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01517.x     Document Type: Article

References (30)

1. Hagell P, Nordling S, Reimer J, Grabowski M, Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov Disord 2002;17:1213-20.
2. Winter Y, Von Campenhausen S, Reese JP et al. Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian Cohort Study. Neurodegener Dis 2010;7:365-72.
3. Winter Y, Balzer-Geldsetzer M, Von Campenhausen S et al. Trends in resource utilization for Parkinson's disease in Germany. J Neurol Sci 2010;294:18-22.
4. Winter Y, Balzer-Geldsetzer M, Spottke A et al. Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany. Eur J Neurol 2010;17:1156-63.
5. Vossius C, Nilsen OB, Larsen JP. Parkinson's disease and hospital admissions: frequencies, diagnoses and costs. Acta Neurol Scand 2010;121:38-43.
6. Siderowf AD, Holloway RG, Stern MB. Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions. Mov Disord 2000;15:439-45.
7. Scheife RT, Schumock GT, Burstein A, Gottwold MD, Luer MS. Impact of Parkinson's disease and its pharmacological treatment on quality of life and economic outcomes. Am J Health Syst Pharm 2000;57:953-62.
8. LePen C, Wait S, Motard-Martin F, Dujardin M, Ziégler M. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999;16:59-69.
9. Anell A, Willis M. International comparison of healthcare systems using resource profiles. Bull World Health Organ 2000;78:770-8.
10. Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. Neurology 2001;57:663-71.
11. Fall PA, Axelsson O, Fredriksson M et al. Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community. J Clin Epidemiol 1996;49:637-41.
12. Abasolo-Osinaga E, Abecia-Inchaurregui LC, Fernández-Díaz E, Barcenilla-Laguna A, Bañares-Onraita T. The prevalence and pharmacological cost of Parkinson's disease in Spain. Rev Neurol 2006;43:641-5.
13. Milanov I, Kmetska K, Karakolev B, Nedialkov E. Prevalence of Parkinson's disease in Bulgaria. Neuroepidemiology 2001;20:212-4.
14. Ljunggren G, Emilsson T. Parkinsonpatienter i Stockholms Läns Landsting åren 2000-2009 och deras vårdkonsumtion. Stockholm: Medicinskt Kunskapscentrum, 2010 (Swedish).
15. International Classification of Diseases.
16. Statistiska Centralbyrån (Swedish) (Annual statistics of Sweden).
17. Apotekens service AB (Swedish) (Pharmacy sales).
18. FASS (Swedish) (Pharmacological specialities in Sweden). LIF. Stockholm: Elanders, 2009.
19. Dodel RC, Singer M, Köhne-Volland R et al. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998;14:299-312.
20. Statistical Methods in Cancer Research Volume II - The Design and Analysis of Cohort Studies. IARC Scientific Publications No. 82. Edited by N. E. Breslow and N. E. Day.
21. Aquilonius S-M, Hartvig P. A Swedish county with unexpectedly high utilisation of anti-Parkinsonian drugs. Acta Neurol Scand 1986;74:379-82.
22. Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson's disease. Mov Disord 2005;20:1449-54.
23. Winter Y, Von Campenhausen S, Brozova H et al. Costs of Parkinson's Disease in eastern Europe: a Czech cohort study. Parkinsonism Relat Disord 2010;16:51-6.
24. Winter Y, Von Campenhausen S, Popov G et al. Costs of illness in a Russian cohort of patients with Parkinson's Disease. Pharmacoeconomics 2009;27:571-842010;16:51-6.
25. Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M. The burden of Parinos's disease on society, family, and the individual. J Am Geriatr Soc 1997;45:844-9.
26. Chrischilles EA, Rubenstein LM, Voelker MD, Wallace RB, Rodnitzky RL. The health burden of Parkinson's disease. Mov Disord 1998;13:406-13.
27. Vargas AP, Carod-Artal FJ, Nunes SV, Melo M. Disability and use of healthcare resources in Brazilian patients with Parkinson's disease. Disabil Rehabil 2008;30:1055-62.
28. Dodel RC, Singer M, Köhne-Volland R et al. Cost of illness in Parkinson's disease. A retrospective 3-month analysis of direct costs. Nervenarzt 1997;68:978-84.
29. Vossius C, Gjerstad M, Baas H, Larsen JP. Drug costs for patients with Parkinson's disease in two different European countries. Acta Neurol Scand 2006;113:228-32.
30. Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Mov Disord 2010;25:474-80.